BioCentury | Sep 30, 2020
Distillery Therapeutics

Endogenous bile acid identified for obesity and diabetes

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Obesity; diabetes GPBAR1 agonism via cholic acid-7-sulfate, a gut-restricted endogenous bile acid, could treat obesity and Type II diabetes. In people who had undergone sleeve gastronomy, post-surgery fecal samples had higher levels...
BioCentury | Sep 3, 2019
Clinical News

Ardelyx gains on Phase III hyperphosphatemia combination data

Ardelyx's tenapanor combination met all endpoints in the Phase III AMPLIFY trial for hyperphosphatemia, setting the stage for a planned 2020 NDA submission once it has long-term monotherapy safety data in hand. Ardelyx Inc. (NASDAQ:ARDX)...
BioCentury | Feb 9, 2018
Product R&D

R is for readout

While AstraZeneca plc gets credit for transparency in publishing its metrics on R&D productivity, the data cover well-established targets addressed by conventional modalities. The more telling test for its “5R framework” will be whether it...
BioCentury | Dec 15, 2017
Company News

Fosun gets Chinese rights to Ardelyx's tenapanor

Gastrointestinal company Ardelyx Inc. (NASDAQ:ARDX) granted Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) exclusive rights in China to develop and commercialize tenapanor (AZD1722, RDX5791) to treat irritable bowel syndrome with constipation (IBS-C) and to...
BioCentury | Dec 12, 2017
Company News

Fosun gets Chinese rights for Ardelyx's tenapanor

Gastrointestinal company Ardelyx Inc. (NASDAQ:ARDX) granted Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) exclusive rights in China to develop and commercialize tenapanor (AZD1722, RDX5791) to treat irritable bowel syndrome with constipation (IBS-C) and to...
BioCentury | Dec 1, 2017
Clinical News

Ardelyx discontinues development of hyperkalemia candidate RDX7675

In a pipeline update Nov. 21, Ardelyx Inc. (NASDAQ:ARDX) said it will discontinue development of hyperkalemia candidate RDX7675 after observing an unexpected, treatment-related side effect of reduced serum bicarbonate levels in a Phase II trial....
BioCentury | Nov 21, 2017
Clinical News

Ardelyx discontinuing hyperkalemia candidate

In a pipeline update Tuesday, Ardelyx Inc. (NASDAQ:ARDX) said it will discontinue development of hyperkalemia candidate RDX7675 after observing an unexpected, treatment-related side effect of reduced serum bicarbonate levels in a Phase II trial. The...
BioCentury | Oct 13, 2017
Clinical News

Ardelyx's tenapanor meets in second Phase III for IBS-C

Ardelyx Inc. (NASDAQ:ARDX) plans to submit an NDA to FDA in 2H18 for tenapanor (AZD1722, RDX5791) to treat irritable bowel syndrome with constipation (IBS-C) after reporting that the compound met the primary and secondary endpoints...
BioCentury | Oct 11, 2017
Clinical News

Ardelyx planning NDA for IBS-C candidate

Ardelyx Inc. (NASDAQ:ARDX) plans to submit an NDA to FDA in 2H18 for tenapanor ( RDX5791 ) to treat irritable bowel syndrome with constipation after it said Wednesday that the compound met the primary and secondary endpoints...
BioCentury | May 19, 2017
Clinical News

Ardelyx reports Phase III tenapanor data in IBS-C

Ardelyx Inc. (NASDAQ:ARDX) said tenapanor (AZD1722, RDX5791) met the primary endpoint in the 12-week, double-blind, placebo-controlled, U.S. Phase III T3MPO-1 trial in 610 patients with irritable bowel syndrome with constipation (IBS-C). Specifically, tenapanor led to...
Items per page:
1 - 10 of 42